Követés
Yana Pikman
Yana Pikman
Dana-Farber Cancer Institute
E-mail megerősítve itt: dfci.harvard.edu
Cím
Hivatkozott rá
Hivatkozott rá
Év
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Y Pikman, BH Lee, T Mercher, E McDowell, BL Ebert, M Gozo, A Cuker, ...
PLoS medicine 3 (7), e270, 2006
17522006
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, ...
Blood 108 (10), 3472-3476, 2006
13202006
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
X Lu, R Levine, W Tong, G Wernig, Y Pikman, S Zarnegar, DG Gilliland, ...
Proceedings of the National Academy of Sciences 102 (52), 18962-18967, 2005
3742005
SYK is a critical regulator of FLT3 in acute myeloid leukemia
A Puissant, N Fenouille, G Alexe, Y Pikman, CF Bassil, S Mehta, J Du, ...
Cancer cell 25 (2), 226-242, 2014
1522014
Targeting MTHFD2 in acute myeloid leukemia
Y Pikman, A Puissant, G Alexe, A Furman, LM Chen, SM Frumm, L Ross, ...
Journal of Experimental Medicine 213 (7), 1285-1306, 2016
1312016
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model
T Mercher, GD Raffel, SA Moore, MG Cornejo, D Baudry-Bluteau, ...
The Journal of clinical investigation 119 (4), 852-864, 2009
1142009
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia
Y Pikman, G Alexe, G Roti, AS Conway, A Furman, ES Lee, AE Place, ...
Clinical Cancer Research 23 (4), 1012-1024, 2017
972017
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
N Fenouille, CF Bassil, I Ben-Sahra, L Benajiba, G Alexe, A Ramos, ...
Nature medicine 23 (3), 301-313, 2017
952017
Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia
FF Wagner, L Benajiba, AJ Campbell, M Weïwer, JR Sacher, JP Gale, ...
Science translational medicine 10 (431), eaam8460, 2018
842018
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray
N Kawamata, S Ogawa, G Yamamoto, S Lehmann, RL Levine, Y Pikman, ...
Experimental hematology 36 (11), 1471-1479, 2008
632008
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
EB Heikamp, JA Henrich, F Perner, EM Wong, C Hatton, Y Wen, ...
Blood, The Journal of the American Society of Hematology 139 (6), 894-906, 2022
552022
Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia
AE Place, Y Pikman, KE Stevenson, MH Harris, M Pauly, ML Sulis, ...
Pediatric blood & cancer 65 (7), e27062, 2018
512018
Identification of prognostic factors in childhood T‐cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05‐001 and 11‐001
MA Burns, AE Place, KE Stevenson, A Gutiérrez, S Forrest, Y Pikman, ...
Pediatric blood & cancer 68 (1), e28719, 2021
372021
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy
Y Pikman, N Ocasio-Martinez, G Alexe, B Dimitrov, S Kitara, FF Diehl, ...
Leukemia 36 (2), 348-360, 2022
352022
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma
AC Wilke, C Doebele, A Zindel, KS Lee, SA Rieke, M Ceribelli, ...
Blood, The Journal of the American Society of Hematology 139 (4), 538-553, 2022
312022
Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor
B Roux, C Vaganay, JD Vargas, G Alexe, C Benaksas, B Pardieu, ...
Science translational medicine 13 (587), eabg1168, 2021
302021
Resistance mechanisms to SYK inhibition in acute myeloid leukemia
A Cremer, JM Ellegast, G Alexe, ES Frank, L Ross, SH Chu, Y Pikman, ...
Cancer discovery 10 (2), 214-231, 2020
302020
Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium
Y Pikman, SK Tasian, ML Sulis, K Stevenson, TM Blonquist, ...
Cancer discovery 11 (6), 1424-1439, 2021
232021
Targeted therapy for fusion-driven high-risk acute leukemia
Y Pikman, K Stegmaier
Blood, The Journal of the American Society of Hematology 132 (12), 1241-1247, 2018
232018
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
BJ Aubrey, JA Cutler, W Bourgeois, KA Donovan, S Gu, C Hatton, ...
Nature cancer 3 (5), 595-613, 2022
182022
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20